Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be
influenced by individual clinical features or by patterns of risk factors and comorbidities. We …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …

Objective To investigate the associations between direct oral anticoagulants (DOACs) and
risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality …

Background: Lifelong oral anticoagulation, either with warfarin or a non–vitamin K
antagonist oral anticoagulant (NOAC), is indicated for stroke prevention in most patients with …

Objective To determine the real world risk of gastrointestinal bleeding associated with the
use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin …

Importance Dabigatran and rivaroxaban are non–vitamin K oral anticoagulants approved for
stroke prevention in patients with nonvalvular atrial fibrillation (AF). There are no …

Background & Aims Use of dabigatran, an inhibitor of thrombin, increases the risk of
gastrointestinal bleeding (GIB). However, it is not clear whether gastroprotective agents …

Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

Background: The role of differing levels of frailty in the choice of oral anticoagulants for older
adults with atrial fibrillation (AF) is unclear. Objective: To examine the outcomes of direct oral …